Company intelligence / Profile preview
Janux Therapeutics
San Diego, California, USAjanuxrx.com ↗
- Ownership
- Public · JANX
- Development stage
- Phase 1
01
Overview
The company has reported encouraging safety and efficacy data from ongoing Phase I dose escalation trials for its two lead programs: JANX007 targeting PSMA in metastatic castration-resistant prostate cancer, and JANX008 targeting EGFR in multiple solid tumors. Both candidates have demonstrated manageable safety profiles with preliminary signs of anti-tumor activity. Additional TRACTr and TRACIr programs are advancing through discovery or IND-enabling stages.[5][7][4]
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesT cell engagers (TCEs)Immunomodulators
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Financials
- Market cap
- $981.9M
- Total revenue
- $10M
- Enterprise value
- $56.5M
Beyond the preview
Go deeper on Janux Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Janux Therapeutics.